An Open label study to evaluate the long term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema (NCT04739059)
CSL312-3002
This trial is No longer recruiting
Registration number NCT04739059
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Celia Zubrinich
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.